Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Françoise Farace,Françoise Farace,Claire Mathiot,Maud Brandely,Thomas Tursz,Thierry Dorval,Pierre Pouillart,Frederic Triebel,Frederic Triebel,Thierry Hercend,Thierry Hercend,Wolf H. Fridman +11 more
20
TL;DR: It is suggested that immune stimulation by rIL‐2 occurs even at low doses and is maximal at a dose below the MTD; and that pretreatment with low‐dose rlFN‐γ does not modify the immune stimulationBy ril‐2.
read more
Abstract: Alterations of immunological parameters were analysed in patients with advanced malignancies during a phase I trial with rIL-2. Five-day infusions of rIL-2 at doses from 1 x 10(6) to 24 x 10(6) biological response modifiers program (BRMP) U/m2 per day were given to 29 patients, with a minimum of three patients per dose. The dose of 24 x 10(6) U/m2 per day was the maximal tolerated dose (MTD). Immunological parameters were analyzed at days 0, 8 and 11 of the rIL-2 courses. Following a leucopenia during rIL-2 infusion, a lymphocytosis was found in all patients except one. The lymphocytosis peaked at day 8 and was detected at doses of rIL-2 as low as 1 x 10(6) U/m2 per day, reaching a plateau at a dose of 16 x 10(6) U/m2 per day. Although all lymphocyte subsets were increased in patients receiving rIL-2, some patients had predominant T cells (CD3+, NKH1(CD56)-), others had predominant natural killer (NK) cells (CD3-, NKH1 (CD56)+), and yet others showed a mixed profile. A strong induction of cells cytotoxic for K562 targets was found in all patients at days 8 and 11. Eighteen patients received, 1 month later, a second treatment in which infusion of rIL-2 was preceded by a course of 5 days infusion of 2 x 10(6) U/m2 per day recombinant interferon-gamma (rIFN-gamma). The infusion of rIFN-gamma prior to rIL-2 had no effect on the rIL-2-induced alterations of immunological parameters. Taken together, our results suggest that immune stimulation by rIL-2 occurs even at low doses and is maximal at a dose below the MTD; and that pretreatment with low-dose rIFN-gamma does not modify the immune stimulation by rIL-2.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Immunotherapy of metastatic renal cell cancer
TL;DR: Kidney CancerRenal Cell CarcinomaIn Vivo Characterization of Syngeneic, Orthotopic Mouse Model of Cox-2 Positive Renal Cell Cancer, an Issue of Urologic Clinics E-Book.
43
Countermeasures for ameliorating in-flight immune dysfunction.
TL;DR: In-flight disturbances of T and NK cell functions are quite significant and could cause some diseases, however, to date the in-flight immune dysfunctions have not been excessive and it is reasonable to consider stress-related immunotherapy approaches in the practice of space medicine.
27
Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma
Bernard Escudier,Sami Antoun,B. Leclercq,Gérard Nitenberg,Françoise Farace,Eric Angevin,Frédéric Triebel,Thierry Hercend,A. Aboudaram,M. Brandely +9 more
TL;DR: Immunological profile observed with this regimen showed a major increase in natural killer cells which became the predominant lymphocyte population at the end of the therapy, increasing acceptability of the regimen by the patients.
25
Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon α : Evidence of a risk/benefit advantage of subcutaneous therapy
TL;DR: It is concluded that palliative low to intermediate-dose s.c. rIL-2/rIFNα combination therapy, in contrast to i.v. treatment, can be administered in the ambulatory setting with good practicability and excellent safety and is as effective against metastatic renal cell cancer as the most aggressive i.V. rII-2 therapy.
21
Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma.
Christina J. Kim,Jeffery K. Taubenberger,Toni B. Simonis,Donald E. White,Steven A. Rosenberg,Francesco M. Marincola +5 more
TL;DR: It is concluded that further studies looking at this combination treatment with IFN-gamma and IL-2 in patients with metastatic melanoma is not warranted and no increased toxicities were found.
18
References
•Journal Article
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.
David M. Jablons,James J. Mulé,Joe K. McIntosh,P B Sehgal,L T May,C M Huang,Steven A. Rosenberg,Michael T. Lotze +7 more
TL;DR: It is concluded that rTNF administration in man leads to the induction of circulating IL-6 which, due to its broad range of activities, may be an important physiologic signal regulating the immune response.
208
•Journal Article
Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
TL;DR: Results suggested that endogenous IFN-gamma was required for rIL 2-induction of AK cells and proliferative response, and were consistent with the hypothesis that AK generation involves a collaboration between IL 2 and IFN -gamma.
195
•Journal Article
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
Paul M. Sondel,Peter C. Kohler,Jacquelyn A. Hank,Karen H. Moore,Rosenthal Ns,Jeffrey A. Sosman,Robin Bechhofer,Barry E. Storer +7 more
TL;DR: A relatively well tolerated immunotherapy regimen using IL-2 can induce dramatic increases in lymphocyte number and augment their in vitro antitumor reactivity.
164
Interferon: a cytotoxic T lymphocyte differentiation signal.
Li-Kuang Chen,Bcatrice Tourvieille,Gordon F. Burns,Fritz H. Bach,Danièle Mathieu-Mahul,Marilyne Sasportes,Armand Bensussan +6 more
TL;DR: Human T cell clones which were able to proliferate in response to specific stimuli but could not kill even in the presence of lectins were found to acquire the specific lytic function when interferon alpha or gamma was added on day 1 of the 7‐day restimulation culture, demonstrating that interferons may act as a cytotoxic T lymphocyte differentiation signal.
126
•Journal Article
Lymphokine-activated Killer Activity Induced by in Vivo Interleukin 2 Therapy: Predominant Role for Lymphocytes with Increased Expression of CD2 and Leu19 Antigens but Negative Expression of CD16 Antigens
Gilda Weil-Hillman,Paul Fisch,Audrey F. Prieve,Jeffrey A. Sosman,Jacquelyn A. Hank,Paul M. Sondel +5 more
TL;DR: The phenotype and function of lymphocytes from cancer patients treated with repetitive weekly cycles of continuous i.v. infusions of recombinant interleukin 2 (IL-2) showed that the predominant population mediating in vitro LAK activity, induced by in vivo IL-2 therapy, consists of activated natural killer cells with a high density of leu19 and CD2 antigens but negative for the CD16 antigen.
92